Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Jul 07, 2020 8:01am
81 Views
Post# 31232502

RE:RE:RE:RE:RE:R+F New Product Launch July 9th

RE:RE:RE:RE:RE:R+F New Product Launch July 9thI think the point you may be missing, and its a big one, is that if the product sales launch is successful with Rodan as a first highly credible customer, that holds tremendous value for the future of not just this compound, but for the scientific platform of florination carbohydrates based chemistry, from a market acceptance standpoint. We are not going to get rich in the next quarter financials from Rodan sales but we may very well hit the mark as more and more deals come through the door which I personally believe will hapoen. If anyone is counting on big $$ from R&F then move on. But the future prospects alone has high value for some shareholders.

As for the continued noise we here on this board, I would suggest you either ignore or report abuse under the long list of violations that can suit the need. Eventually they will  get removed as they did last time. 
Bullboard Posts